Delivery Order SPE2DR25D3504-SPE2DR26F7BL4
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,001.46 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with a completion date of November 7, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement,...
- The Defense Logistics Agency (DLA) awarded a $27,947.21 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of October 24, 2025. This contract was competitively awarded without set-aside designation and utilizes firm fixed pricing. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this pharmaceutical supply requirement as part of its ongoing federal medical procurement operations supporting...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $7,922.90 firm fixed-price delivery order for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of November 6, 2025. This competitively awarded contract, issued on November 5, 2025, represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania facility, where...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,061.39 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, awarded on October 27, 2025, represents a firm fixed-price delivery order with an ultimate completion date of October 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This non-set-aside award was competitively awarded to AmerisourceBergen, a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,789.92 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of October 31, 2025. This non-competitive delivery order represents a firm fixed-price purchase of specialty pharmaceutical products under the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,202.26 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors on December 3, 2025, with completion scheduled for December 4, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a small-value pharmaceutical procurement through DLA's established contracting mechanisms. AmerisourceBergen Drug Corp, a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $27,880.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 5, 2025. This non-competitive delivery order represents a firm fixed-price purchase under the company's existing contract vehicle with DLA. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,507.05 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and represents a single transaction for pharmaceutical supply to support federal medical needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $5,471.51 delivery order (Contract No. 4570186679) to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. The non-competitive delivery order, issued on December 5, 2025, with completion by December 8, 2025, represents a firm fixed-price transaction under a child contract arrangement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,432.55 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract, which was competitively awarded without set-aside designation, is firm fixed price and scheduled for completion by September 16, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery...
- SPE2DR25D3504Indefinite Delivery Contract
- SPE2DR25D3504-SPE2DR26F7BL4Delivery Order
The Defense Logistics Agency (DLA) awarded a $3,901.00 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with completion targeted for December 5, 2025. This competitively awarded, firm fixed-price contract was issued with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the location of performance—is a major pharmaceutical distributor serving federal medical procurement needs across military and veteran healthcare systems. This delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime vehicle enables the company to supply pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. Repatha (evolocumab), a specialty medication for cholesterol management, exemplifies the type of brand-name therapeutic agent that AmerisourceBergen delivers through its federal pharmaceutical support contract portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.9k | 12/3/25 |